NO320396B1 - 4-okso-1,4-dihydro-3-kinolinkarboksamider, farmasoytiske preparater som omfatter forbindelsene og anvendelse av forbindelsene til fremstilling av medikamenter for behandling av herpesvirusinfeksjon, samt mellomproduktforbindelser ved og fremgangsmate for fremstilling av ett av karboksamidene. - Google Patents
4-okso-1,4-dihydro-3-kinolinkarboksamider, farmasoytiske preparater som omfatter forbindelsene og anvendelse av forbindelsene til fremstilling av medikamenter for behandling av herpesvirusinfeksjon, samt mellomproduktforbindelser ved og fremgangsmate for fremstilling av ett av karboksamidene. Download PDFInfo
- Publication number
- NO320396B1 NO320396B1 NO20013379A NO20013379A NO320396B1 NO 320396 B1 NO320396 B1 NO 320396B1 NO 20013379 A NO20013379 A NO 20013379A NO 20013379 A NO20013379 A NO 20013379A NO 320396 B1 NO320396 B1 NO 320396B1
- Authority
- NO
- Norway
- Prior art keywords
- oxo
- methyl
- dihydro
- chlorobenzyl
- quinolinecarboxamide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 107
- 238000002360 preparation method Methods 0.000 title claims description 24
- 238000000034 method Methods 0.000 title claims description 19
- 208000029433 Herpesviridae infectious disease Diseases 0.000 title claims description 4
- 239000003814 drug Substances 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title description 20
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- CVAWACBLSANHSQ-UHFFFAOYSA-N 4-oxo-1h-quinoline-3-carboxamide Chemical class C1=CC=CC2=C(O)C(C(=O)N)=CN=C21 CVAWACBLSANHSQ-UHFFFAOYSA-N 0.000 title description 2
- 150000003857 carboxamides Chemical class 0.000 title description 2
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052717 sulfur Chemical group 0.000 claims abstract description 4
- 239000011593 sulfur Chemical group 0.000 claims abstract description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 24
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 8
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 8
- 241000701022 Cytomegalovirus Species 0.000 claims description 7
- SXLQSQMKOYVAAW-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-1-methyl-6-(morpholin-4-ylmethyl)-4-oxoquinoline-3-carboxamide Chemical compound O=C1C2=CC(CN3CCOCC3)=CC=C2N(C)C=C1C(=O)NCC1=CC=C(Cl)C=C1 SXLQSQMKOYVAAW-UHFFFAOYSA-N 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 241001529453 unidentified herpesvirus Species 0.000 claims description 7
- LTMHNWPUDSTBKD-UHFFFAOYSA-N diethyl 2-(ethoxymethylidene)propanedioate Chemical compound CCOC=C(C(=O)OCC)C(=O)OCC LTMHNWPUDSTBKD-UHFFFAOYSA-N 0.000 claims description 6
- JZMLFSIIGJNNMS-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-8-fluoro-1-methyl-6-(morpholin-4-ylmethyl)-4-oxoquinoline-3-carboxamide Chemical compound O=C1C2=CC(CN3CCOCC3)=CC(F)=C2N(C)C=C1C(=O)NCC1=CC=C(Cl)C=C1 JZMLFSIIGJNNMS-UHFFFAOYSA-N 0.000 claims description 6
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- XAKZVPHHQYZVTC-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-6-(3-hydroxypropyl)-1-methyl-4-oxoquinoline-3-carboxamide Chemical compound O=C1C2=CC(CCCO)=CC=C2N(C)C=C1C(=O)NCC1=CC=C(Cl)C=C1 XAKZVPHHQYZVTC-UHFFFAOYSA-N 0.000 claims description 5
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 claims description 5
- 241000701041 Human betaherpesvirus 7 Species 0.000 claims description 4
- 241000701027 Human herpesvirus 6 Species 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- YZDSPQZLIFDLEX-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-1-(2-hydroxyethyl)-6-(3-hydroxypropyl)-4-oxoquinoline-3-carboxamide Chemical compound O=C1C2=CC(CCCO)=CC=C2N(CCO)C=C1C(=O)NCC1=CC=C(Cl)C=C1 YZDSPQZLIFDLEX-UHFFFAOYSA-N 0.000 claims description 4
- XLOIHBHFDPPKJF-UHFFFAOYSA-N 1-methyl-6-(morpholin-4-ylmethyl)-4-oxoquinoline-3-carboxylic acid Chemical compound C=1C=C2N(C)C=C(C(O)=O)C(=O)C2=CC=1CN1CCOCC1 XLOIHBHFDPPKJF-UHFFFAOYSA-N 0.000 claims description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- PUDBJWPSCYEPQY-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-6-(4-hydroxy-2-methylbutan-2-yl)-1-methyl-4-oxoquinoline-3-carboxamide Chemical compound O=C1C2=CC(C(C)(C)CCO)=CC=C2N(C)C=C1C(=O)NCC1=CC=C(Cl)C=C1 PUDBJWPSCYEPQY-UHFFFAOYSA-N 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- LFANOUKRAFHSAO-UHFFFAOYSA-N ethyl 1-methyl-6-(morpholin-4-ylmethyl)-4-oxoquinoline-3-carboxylate Chemical compound C1=C2C(=O)C(C(=O)OCC)=CN(C)C2=CC=C1CN1CCOCC1 LFANOUKRAFHSAO-UHFFFAOYSA-N 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- OELUZVAXTQPFAY-UHFFFAOYSA-N n-methyl-4-(morpholin-4-ylmethyl)aniline Chemical compound C1=CC(NC)=CC=C1CN1CCOCC1 OELUZVAXTQPFAY-UHFFFAOYSA-N 0.000 claims description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- NRYVQTMJRSWWFR-UHFFFAOYSA-N 1-tert-butyl-n-[(4-chlorophenyl)methyl]-6-(3-hydroxypropyl)-4-oxoquinoline-3-carboxamide Chemical compound O=C1C2=CC(CCCO)=CC=C2N(C(C)(C)C)C=C1C(=O)NCC1=CC=C(Cl)C=C1 NRYVQTMJRSWWFR-UHFFFAOYSA-N 0.000 claims 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 11
- 125000003545 alkoxy group Chemical group 0.000 abstract description 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 7
- 239000003443 antiviral agent Substances 0.000 abstract description 6
- 125000005842 heteroatom Chemical group 0.000 abstract description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 102
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 86
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 38
- 239000007787 solid Substances 0.000 description 36
- 239000011541 reaction mixture Substances 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 31
- 239000000243 solution Substances 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 239000000047 product Substances 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 239000000377 silicon dioxide Substances 0.000 description 14
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 230000000704 physical effect Effects 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 239000002002 slurry Substances 0.000 description 8
- -1 COCF3 Chemical group 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical group 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- QNNJHBNTHVHALE-UHFFFAOYSA-N 2-fluoro-5-iodobenzoic acid Chemical compound OC(=O)C1=CC(I)=CC=C1F QNNJHBNTHVHALE-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- ZSEUEKCXNXRIKT-UHFFFAOYSA-N [N].O=C1C=CC=CN1 Chemical compound [N].O=C1C=CC=CN1 ZSEUEKCXNXRIKT-UHFFFAOYSA-N 0.000 description 3
- 150000007929 acylimidazolides Chemical class 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- LHCASPYXLIAHLU-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-6-(3-hydroxyprop-1-ynyl)-4-oxo-1h-quinoline-3-carboxamide Chemical compound O=C1C2=CC(C#CCO)=CC=C2NC=C1C(=O)NCC1=CC=C(Cl)C=C1 LHCASPYXLIAHLU-UHFFFAOYSA-N 0.000 description 3
- 238000002821 scintillation proximity assay Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 2
- KGNQDBQYEBMPFZ-UHFFFAOYSA-N 1-fluoro-4-iodobenzene Chemical compound FC1=CC=C(I)C=C1 KGNQDBQYEBMPFZ-UHFFFAOYSA-N 0.000 description 2
- WCGJULUEWLXHDK-UHFFFAOYSA-N 1-tert-butyl-n-[(4-chlorophenyl)methyl]-6-iodo-4-oxoquinoline-3-carboxamide Chemical compound O=C1C2=CC(I)=CC=C2N(C(C)(C)C)C=C1C(=O)NCC1=CC=C(Cl)C=C1 WCGJULUEWLXHDK-UHFFFAOYSA-N 0.000 description 2
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- ITGQCQGQYJVSPE-UHFFFAOYSA-N 3-methyl-3-(4-nitrophenyl)butanoic acid Chemical compound OC(=O)CC(C)(C)C1=CC=C([N+]([O-])=O)C=C1 ITGQCQGQYJVSPE-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- VLVCDUSVTXIWGW-UHFFFAOYSA-N 4-iodoaniline Chemical compound NC1=CC=C(I)C=C1 VLVCDUSVTXIWGW-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 208000001860 Eye Infections Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000007098 aminolysis reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 230000006315 carbonylation Effects 0.000 description 2
- 238000005810 carbonylation reaction Methods 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- NSMXQKAXPPSXLC-UHFFFAOYSA-N ethyl 3-(2-fluoro-5-iodophenyl)-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)C1=CC(I)=CC=C1F NSMXQKAXPPSXLC-UHFFFAOYSA-N 0.000 description 2
- NPZATCMFCFASBE-UHFFFAOYSA-N ethyl 6-iodo-4-oxo-1h-quinoline-3-carboxylate Chemical compound C1=C(I)C=C2C(=O)C(C(=O)OCC)=CNC2=C1 NPZATCMFCFASBE-UHFFFAOYSA-N 0.000 description 2
- 208000011323 eye infectious disease Diseases 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- MQPUQODQYTZESW-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-1-(2-hydroxyethyl)-6-(3-hydroxyprop-1-ynyl)-4-oxoquinoline-3-carboxamide Chemical compound O=C1C2=CC(C#CCO)=CC=C2N(CCO)C=C1C(=O)NCC1=CC=C(Cl)C=C1 MQPUQODQYTZESW-UHFFFAOYSA-N 0.000 description 2
- GTDICRLTAZZQIY-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-1-methyl-4-oxo-6-(thiomorpholin-4-ylmethyl)quinoline-3-carboxamide Chemical compound O=C1C2=CC(CN3CCSCC3)=CC=C2N(C)C=C1C(=O)NCC1=CC=C(Cl)C=C1 GTDICRLTAZZQIY-UHFFFAOYSA-N 0.000 description 2
- XAHYNNBFGCRARB-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-6-(hydroxymethyl)-1-methyl-4-oxoquinoline-3-carboxamide Chemical compound O=C1C2=CC(CO)=CC=C2N(C)C=C1C(=O)NCC1=CC=C(Cl)C=C1 XAHYNNBFGCRARB-UHFFFAOYSA-N 0.000 description 2
- PUJOTKBPZPNSDZ-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-6-iodo-4-oxo-1h-quinoline-3-carboxamide Chemical compound C1=NC2=CC=C(I)C=C2C(O)=C1C(=O)NCC1=CC=C(Cl)C=C1 PUJOTKBPZPNSDZ-UHFFFAOYSA-N 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- ZHHAHKVCMVHXTM-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-4-oxoquinoline-3-carboxamide Chemical compound C12=CC=CC=C2C(=O)C(C(=O)N)=CN1CC1=CC=C(Cl)C=C1 ZHHAHKVCMVHXTM-UHFFFAOYSA-N 0.000 description 1
- DVVGIUUJYPYENY-UHFFFAOYSA-N 1-methylpyridin-2-one Chemical compound CN1C=CC=CC1=O DVVGIUUJYPYENY-UHFFFAOYSA-N 0.000 description 1
- DOKDBHHYJUPFIB-UHFFFAOYSA-N 1-tert-butyl-n-[(4-chlorophenyl)methyl]-6-(3-hydroxyprop-1-ynyl)-4-oxoquinoline-3-carboxamide Chemical compound O=C1C2=CC(C#CCO)=CC=C2N(C(C)(C)C)C=C1C(=O)NCC1=CC=C(Cl)C=C1 DOKDBHHYJUPFIB-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- JHNLZOVBAQWGQU-UHFFFAOYSA-N 380814_sial Chemical compound CS(O)(=O)=O.O=P(=O)OP(=O)=O JHNLZOVBAQWGQU-UHFFFAOYSA-N 0.000 description 1
- SBBDHANTMHIRGW-UHFFFAOYSA-N 4-[(2,4-dihydroxy-3,3-dimethylbutanoyl)amino]butanoic acid Chemical compound OCC(C)(C)C(O)C(=O)NCCCC(O)=O SBBDHANTMHIRGW-UHFFFAOYSA-N 0.000 description 1
- DTKVELQNIALZOC-UHFFFAOYSA-N 6-iodo-4-oxo-1h-quinoline-3-carboxamide Chemical compound C1=CC(I)=CC2=C(O)C(C(=O)N)=CN=C21 DTKVELQNIALZOC-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- RYGMFSIKBFXOCR-NJFSPNSNSA-N copper-66 Chemical compound [66Cu] RYGMFSIKBFXOCR-NJFSPNSNSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- BRLALEQUTCSHFF-UHFFFAOYSA-N diethyl 2-[[n-methyl-4-(morpholin-4-ylmethyl)anilino]methylidene]propanedioate Chemical compound C1=CC(N(C)C=C(C(=O)OCC)C(=O)OCC)=CC=C1CN1CCOCC1 BRLALEQUTCSHFF-UHFFFAOYSA-N 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- GMVIQOCPXTZUFJ-UHFFFAOYSA-L dipotassium;2-ethylpropanedioate Chemical compound [K+].[K+].CCC(C([O-])=O)C([O-])=O GMVIQOCPXTZUFJ-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- SSPWBSFNLQBDRT-UHFFFAOYSA-N ethyl 1-tert-butyl-6-iodo-4-oxoquinoline-3-carboxylate Chemical compound C1=C(I)C=C2C(=O)C(C(=O)OCC)=CN(C(C)(C)C)C2=C1 SSPWBSFNLQBDRT-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- MXZNVMWTLSQNME-UHFFFAOYSA-N methyl 3-[(4-chlorophenyl)methylcarbamoyl]-4-oxo-1h-quinoline-6-carboxylate Chemical compound OC=1C2=CC(C(=O)OC)=CC=C2N=CC=1C(=O)NCC1=CC=C(Cl)C=C1 MXZNVMWTLSQNME-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- MNTDJRIXQBIUHE-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-6-(3-hydroxyprop-1-ynyl)-1-methyl-4-oxoquinoline-3-carboxamide Chemical compound O=C1C2=CC(C#CCO)=CC=C2N(C)C=C1C(=O)NCC1=CC=C(Cl)C=C1 MNTDJRIXQBIUHE-UHFFFAOYSA-N 0.000 description 1
- UKPAHXXJLLGLPU-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-6-(hydroxymethyl)-4-oxo-1h-quinoline-3-carboxamide Chemical compound OC=1C2=CC(CO)=CC=C2N=CC=1C(=O)NCC1=CC=C(Cl)C=C1 UKPAHXXJLLGLPU-UHFFFAOYSA-N 0.000 description 1
- VTSYTXVCWKJNET-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-8-fluoro-6-(morpholin-4-ylmethyl)-4-oxo-1h-quinoline-3-carboxamide Chemical compound C1=C2C(O)=C(C(=O)NCC=3C=CC(Cl)=CC=3)C=NC2=C(F)C=C1CN1CCOCC1 VTSYTXVCWKJNET-UHFFFAOYSA-N 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- PMZDQRJGMBOQBF-UHFFFAOYSA-N quinolin-4-ol Chemical compound C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 229930185107 quinolinone Natural products 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 238000001149 thermolysis Methods 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- MBMQEIFVQACCCH-QBODLPLBSA-N zearalenone Chemical compound O=C1O[C@@H](C)CCCC(=O)CCC\C=C\C2=CC(O)=CC(O)=C21 MBMQEIFVQACCCH-QBODLPLBSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11511399P | 1999-01-08 | 1999-01-08 | |
| US13839099P | 1999-06-09 | 1999-06-09 | |
| US14061499P | 1999-06-23 | 1999-06-23 | |
| PCT/US1999/027959 WO2000040563A1 (en) | 1999-01-08 | 1999-12-22 | 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20013379D0 NO20013379D0 (no) | 2001-07-06 |
| NO20013379L NO20013379L (no) | 2001-07-06 |
| NO320396B1 true NO320396B1 (no) | 2005-11-28 |
Family
ID=27381602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20013379A NO320396B1 (no) | 1999-01-08 | 2001-07-06 | 4-okso-1,4-dihydro-3-kinolinkarboksamider, farmasoytiske preparater som omfatter forbindelsene og anvendelse av forbindelsene til fremstilling av medikamenter for behandling av herpesvirusinfeksjon, samt mellomproduktforbindelser ved og fremgangsmate for fremstilling av ett av karboksamidene. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6248736B1 (de) |
| EP (1) | EP1140851B1 (de) |
| JP (1) | JP2002534417A (de) |
| KR (1) | KR20010101428A (de) |
| CN (1) | CN1132818C (de) |
| AT (1) | ATE275134T1 (de) |
| AU (1) | AU2158300A (de) |
| BR (1) | BR9916781A (de) |
| CA (1) | CA2353634A1 (de) |
| CO (1) | CO5150150A1 (de) |
| CZ (1) | CZ20012458A3 (de) |
| DE (1) | DE69919897T2 (de) |
| EA (1) | EA004043B1 (de) |
| ES (1) | ES2228162T3 (de) |
| HK (1) | HK1041879A1 (de) |
| HU (1) | HUP0105142A3 (de) |
| ID (1) | ID29452A (de) |
| IL (1) | IL144170A0 (de) |
| MY (1) | MY118904A (de) |
| NO (1) | NO320396B1 (de) |
| NZ (1) | NZ512823A (de) |
| PE (1) | PE20001337A1 (de) |
| PL (1) | PL348769A1 (de) |
| PT (1) | PT1140851E (de) |
| SK (1) | SK8312001A3 (de) |
| TR (1) | TR200101893T2 (de) |
| TW (1) | TW593281B (de) |
| WO (1) | WO2000040563A1 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6730682B2 (en) | 2000-07-12 | 2004-05-04 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| US6562822B2 (en) | 2000-07-12 | 2003-05-13 | Pharmacia & Upjohn Company | Heterocyle carboxamides as antiviral agents |
| US6559145B2 (en) | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| US6682892B2 (en) * | 2000-07-13 | 2004-01-27 | Pharmacia & Upjohn Company | Method for treating herpes viruses |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| EP1363887A1 (de) * | 2001-03-01 | 2003-11-26 | PHARMACIA & UPJOHN COMPANY | Substituierte chinolincarboxamide und deren verwendung als antivirale mittel |
| WO2003020728A1 (en) | 2001-08-30 | 2003-03-13 | Pharmacia & Upjohn Company | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS |
| AR038294A1 (es) | 2002-01-14 | 2005-01-12 | Upjohn Co | Oxotieno(3,2-b)piridincarboxamidas como agentes antivirales |
| AR038117A1 (es) | 2002-01-14 | 2004-12-29 | Upjohn Co | Agentes antivirales derivados de la 4- oxo-4,7 -dihidrofuro [2,3-b]piridin-5-carboxamida |
| AR038118A1 (es) * | 2002-01-14 | 2004-12-29 | Upjohn Co | Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales |
| AU2003262946A1 (en) * | 2002-08-30 | 2004-03-19 | Pharmacia And Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
| AU2003262947A1 (en) * | 2002-08-30 | 2004-03-19 | Pharmacia And Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
| EP1564210B9 (de) | 2002-11-20 | 2010-03-31 | Japan Tobacco Inc. | 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren |
| CN100375742C (zh) * | 2002-11-20 | 2008-03-19 | 日本烟草产业株式会社 | 4-氧代喹啉化合物及其用途 |
| KR20060041254A (ko) | 2003-07-24 | 2006-05-11 | 아스텔라스세이야쿠 가부시키가이샤 | 퀴놀론 유도체 또는 그의 염 |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| US7531554B2 (en) | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| JP4629104B2 (ja) * | 2004-05-21 | 2011-02-09 | 日本たばこ産業株式会社 | ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤 |
| CN101006076B (zh) | 2004-06-24 | 2010-09-29 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
| US20070032522A1 (en) * | 2005-07-01 | 2007-02-08 | Kumar Dange V | Antiviral agents |
| DK3219705T3 (da) | 2005-12-28 | 2020-04-14 | Vertex Pharma | Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid |
| EP2452682A1 (de) * | 2006-02-01 | 2012-05-16 | Japan Tobacco, Inc. | Verwendung von 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-Carboxysäure oder einem Salz daraus zur Behandlung von einen Retrovireninfektion |
| KR101023635B1 (ko) * | 2006-03-06 | 2011-03-22 | 니뽄 다바코 산교 가부시키가이샤 | 4-옥소퀴놀린 화합물 제조 방법 |
| DE102008036099B4 (de) | 2008-08-04 | 2014-02-13 | Steag Power Saar Gmbh | Entstickungsanlage |
| PT2408750E (pt) | 2009-03-20 | 2015-10-15 | Vertex Pharma | Processo para a produção de modeladores do regulador de condutância transmembranar da fibrose cística |
| WO2011004389A2 (en) | 2009-06-18 | 2011-01-13 | Matrix Laboratories Ltd | An improved process for the preparation of elvitegravir |
| ES2537628T3 (es) * | 2010-08-27 | 2015-06-10 | Grünenthal GmbH | 2-Oxiquinolin-3-carboxamidas sustituidas como moduladores de KCNQ2/3 |
| EP2819670A1 (de) | 2012-02-27 | 2015-01-07 | Vertex Pharmaceuticals Incorporated | Pharmazeutische zusammensetzung und verabreichung davon |
| US9309222B2 (en) | 2012-10-16 | 2016-04-12 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| EP2909189B8 (de) | 2012-10-16 | 2017-04-19 | Janssen Pharmaceutica NV | Heteroarylverknüpfte chinolinyl-modulatoren von ror-gamma-t |
| EA026415B1 (ru) | 2012-10-16 | 2017-04-28 | Янссен Фармацевтика Нв | Связанные с метиленом хинолиниловые модуляторы ror-гамма-t |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| KR20160068956A (ko) | 2013-10-15 | 2016-06-15 | 얀센 파마슈티카 엔.브이. | RORyT의 퀴놀리닐 조절제 |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| JP6423423B2 (ja) | 2013-10-15 | 2018-11-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｒｏｒγｔのアルキル結合キノリニルモジュレーター |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
| WO2020053654A1 (en) | 2018-09-12 | 2020-03-19 | Novartis Ag | Antiviral pyridopyrazinedione compounds |
| KR20220070005A (ko) | 2019-09-26 | 2022-05-27 | 노파르티스 아게 | 항바이러스성 피라졸로피리디논 화합물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2593810B1 (fr) * | 1986-01-24 | 1988-04-22 | Sanofi Sa | Derives de la quinoleine, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant |
| US4786644A (en) * | 1987-11-27 | 1988-11-22 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-quinolinecarboxamide |
| US4959363A (en) * | 1989-06-23 | 1990-09-25 | Sterling Drug Inc. | Quinolonecarboxamide compounds, their preparation and use as antivirals. |
| AU8448491A (en) * | 1990-09-07 | 1992-03-30 | Schering Corporation | Antiviral compounds and antihypertensive compounds |
| US5175151A (en) | 1990-09-07 | 1992-12-29 | Schering Corporation | Antiviral compounds and antihypertensive compounds |
| EP0531578B1 (de) | 1991-09-10 | 1995-12-20 | Agfa-Gevaert N.V. | Thermisch übertragbare fluoreszierende Verbindungen |
| WO1997004779A1 (en) * | 1995-08-02 | 1997-02-13 | Chiroscience Limited | Quinolones and their therapeutic use |
| CN1200114A (zh) | 1995-10-19 | 1998-11-25 | 武田药品工业株式会社 | 作为gnrh拮抗剂的喹啉衍生物 |
| DE69736812T2 (de) | 1996-11-27 | 2007-08-09 | Bristol-Myers Squibb Pharma Co. | Neue integrin rezeptor antagonisten |
| US6093732A (en) | 1997-12-22 | 2000-07-25 | Pharmacia & Upjohn Company | 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents |
-
1999
- 1999-12-17 US US09/465,670 patent/US6248736B1/en not_active Expired - Fee Related
- 1999-12-22 NZ NZ512823A patent/NZ512823A/en unknown
- 1999-12-22 EA EA200100755A patent/EA004043B1/ru not_active IP Right Cessation
- 1999-12-22 ID IDW00200101463A patent/ID29452A/id unknown
- 1999-12-22 JP JP2000592271A patent/JP2002534417A/ja active Pending
- 1999-12-22 CA CA002353634A patent/CA2353634A1/en not_active Abandoned
- 1999-12-22 CZ CZ20012458A patent/CZ20012458A3/cs unknown
- 1999-12-22 PL PL99348769A patent/PL348769A1/xx unknown
- 1999-12-22 CN CN998151602A patent/CN1132818C/zh not_active Expired - Fee Related
- 1999-12-22 KR KR1020017008641A patent/KR20010101428A/ko not_active Application Discontinuation
- 1999-12-22 IL IL14417099A patent/IL144170A0/xx unknown
- 1999-12-22 EP EP99965907A patent/EP1140851B1/de not_active Expired - Lifetime
- 1999-12-22 AU AU21583/00A patent/AU2158300A/en not_active Abandoned
- 1999-12-22 WO PCT/US1999/027959 patent/WO2000040563A1/en active Search and Examination
- 1999-12-22 PT PT99965907T patent/PT1140851E/pt unknown
- 1999-12-22 DE DE69919897T patent/DE69919897T2/de not_active Expired - Fee Related
- 1999-12-22 HU HU0105142A patent/HUP0105142A3/hu unknown
- 1999-12-22 SK SK831-2001A patent/SK8312001A3/sk unknown
- 1999-12-22 BR BR9916781-6A patent/BR9916781A/pt not_active Application Discontinuation
- 1999-12-22 AT AT99965907T patent/ATE275134T1/de not_active IP Right Cessation
- 1999-12-22 TR TR2001/01893T patent/TR200101893T2/xx unknown
- 1999-12-22 ES ES99965907T patent/ES2228162T3/es not_active Expired - Lifetime
- 1999-12-24 MY MYPI99005719A patent/MY118904A/en unknown
- 1999-12-28 PE PE1999001326A patent/PE20001337A1/es not_active Application Discontinuation
- 1999-12-29 CO CO99081336A patent/CO5150150A1/es unknown
-
2000
- 2000-01-07 TW TW089100222A patent/TW593281B/zh not_active IP Right Cessation
-
2001
- 2001-07-06 NO NO20013379A patent/NO320396B1/no unknown
-
2002
- 2002-05-07 HK HK02103436A patent/HK1041879A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2353634A1 (en) | 2000-07-13 |
| WO2000040563A1 (en) | 2000-07-13 |
| ES2228162T3 (es) | 2005-04-01 |
| EA200100755A1 (ru) | 2001-12-24 |
| HUP0105142A3 (en) | 2002-05-28 |
| HUP0105142A2 (hu) | 2002-04-29 |
| NO20013379D0 (no) | 2001-07-06 |
| IL144170A0 (en) | 2002-05-23 |
| ATE275134T1 (de) | 2004-09-15 |
| AU2158300A (en) | 2000-07-24 |
| CO5150150A1 (es) | 2002-04-29 |
| DE69919897D1 (en) | 2004-10-07 |
| ID29452A (id) | 2001-08-30 |
| PE20001337A1 (es) | 2000-11-23 |
| EA004043B1 (ru) | 2003-12-25 |
| PT1140851E (pt) | 2004-12-31 |
| JP2002534417A (ja) | 2002-10-15 |
| EP1140851B1 (de) | 2004-09-01 |
| US6248736B1 (en) | 2001-06-19 |
| NZ512823A (en) | 2003-10-31 |
| TW593281B (en) | 2004-06-21 |
| KR20010101428A (ko) | 2001-11-14 |
| HK1041879A1 (en) | 2002-07-26 |
| SK8312001A3 (en) | 2001-12-03 |
| MY118904A (en) | 2005-02-28 |
| EP1140851A1 (de) | 2001-10-10 |
| TR200101893T2 (tr) | 2001-11-21 |
| CZ20012458A3 (cs) | 2001-12-12 |
| CN1332729A (zh) | 2002-01-23 |
| DE69919897T2 (de) | 2005-09-08 |
| CN1132818C (zh) | 2003-12-31 |
| NO20013379L (no) | 2001-07-06 |
| BR9916781A (pt) | 2001-12-04 |
| PL348769A1 (en) | 2002-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO320396B1 (no) | 4-okso-1,4-dihydro-3-kinolinkarboksamider, farmasoytiske preparater som omfatter forbindelsene og anvendelse av forbindelsene til fremstilling av medikamenter for behandling av herpesvirusinfeksjon, samt mellomproduktforbindelser ved og fremgangsmate for fremstilling av ett av karboksamidene. | |
| EP1042295B1 (de) | 4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe | |
| US6248739B1 (en) | Quinolinecarboxamides as antiviral agents | |
| EP2010496B1 (de) | 4-anilinochinolin-3-carbonsäureamide als csf-1r-kinaseinhibitoren | |
| WO2007038571A2 (en) | Prolyl hydroxylase antagonists | |
| WO2008056148A1 (en) | Chemical compounds | |
| KR20030014320A (ko) | 항바이러스제로서의 피롤로퀴놀론 | |
| CA2433467A1 (en) | Substituted quinolinecarboxamides as antiviral agents | |
| US7723337B2 (en) | 3-cinnolinecarboxamide derivatives and their use for treating cancer | |
| US20110190272A1 (en) | Chemical compounds | |
| MXPA01006911A (en) | 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents | |
| ZA200209531B (en) | 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents. | |
| MXPA01006913A (en) | Quinolinecarboxamides as antiviral agents |